Past catalysts on this ticker, reconciled against the announcement parse pipeline. Hover any row for the parsed outcome detail.
Cxbladder Monitor's own upcoming catalysts alongside class-defining historical readouts and upcoming primary completion dates in the same mechanism classes. Each event moves the broader thesis for Cxbladder Monitor. Showing past 6 months and next 12 months · 6 later hidden.
Same axes, same units. Discontinued and historical pivotal trials excluded; see Competitor Landscape below for the full set.
| Trial | Sponsor | Class | Phase / Line | Design | Primary endpoint | Dosing | Key eligibility | n |
|---|---|---|---|---|---|---|---|---|
| Cxbladder Monitor | Pacific Edge | Diagnostic Device | Approved | 0 | ||||
| Impact of Remimazolam on Prognosis After Bladder Cancer Surgery | Peking University First Hospital | — | Phase 4 |
Read-across commentary attached per trial. Phase ordering preserved within each group.
External analyst notes, journalism, and industry commentary cited with attribution.
"Sponsor guided" dates come from IR materials and earnings calls; hover for the cited source. "CT.gov proxy" dates fall back to the registry primary completion date — actual readouts typically follow by 3-6 months.
| — |
| — |
| — |
| — |
| — |
| Chemoablation Or Bladder Resection With Adjuvant Chemotherapy in Recurrent Non-Muscle Invasive Bladder Cancer | Jakob Kristian Jakobsen | — | Phase 4 | — | — | — | — | — |
| A Phase 3 Single-Arm Study of UGN-102 for Treatment of Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer | UroGen Pharma Ltd. | — | Phase 3 | — | — | — | — | — |
| Multicenter Clinical Trial on the Effectiveness and Safety of Instillation of BCG and Alternative BCG Protocols for Intermediate and High-risk Non-muscle Invasive Bladder Cancer | Fujian Medical University Union Hospital | — | Phase 3 | — | — | — | — | — |
| Clinical Trial for Evaluating the Efficacy and Safety of BCG for Therapeutic Use in the Prevention of Postoperative Recurrence of Medium/High-risk Non-muscle Invasive Bladder Cancer (NMIBC) | Chengdu CoenBiotech Co., Ltd | — | Phase 3 | — | — | — | — | — |
| A Phase 3 Study of UGN-103 for Treatment of Patients With Low-grade Intermediate-risk Non-muscle Invasive Bladder Cancer | UroGen Pharma Ltd. | — | Phase 3 | — | — | — | — | — |
| Single-Dose Intravesical Chemotherapy After Diagnostic URS | David D'Andrea | — | Phase 3 | — | — | — | — | — |
| HIVEC in Patients With Non-Muscle-Invasive Bladder Cancer | Affiliated Cancer Hospital & Institute of Guangzhou Medical University | — | Phase 3 | — | — | — | — | — |
| Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Bacillus Calmette-Guerin (BCG) in High-Risk Non-Muscle Invasive Bladder Cancer (HR NMIBC) (MK-3475-676/KEYNOTE-676) | Merck Sharp & Dohme LLC | — | Phase 3 | — | — | — | — | — |
| BCG for Therapeutic Use Phase Ⅲ Clinical Trial | Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd. | — | Phase 3 | — | — | — | — | — |
| Therapeutic Instillation of Mistletoe | Abnoba Gmbh | — | Phase 3 | — | — | — | — | — |
| Testing the Addition of an Anti-Cancer Drug, Gemcitabine, to Usual Treatment (BCG Alone) in People Whose Non-Muscle Invasive Bladder Cancer (NMIBC) Came Back After Prior BCG Therapy | Alliance for Clinical Trials in Oncology | — | Phase 3 | — | — | — | — | — |
| Evaluating Safety and Efficacy of Verity-BCG in BCG-naïve Patients With Intermediate and High-risk Non-muscle Invasive Bladder (NMIBC) | Verity Pharmaceuticals Inc. | — | Phase 3 | — | — | — | — | — |
| A Study of NDV-01 (Sustained-release Gemcitabine-docetaxel) in Participants With Non-muscle Invasive Bladder Cancer | Relmada Therapeutics, Inc. | — | Phase 3 | — | — | — | — | — |
| A Study of TAR-200 Versus Intravesical Chemotherapy in Participants With Recurrent High-Risk Non-Muscle-Invasive Bladder Cancer (HR-NMIBC) After Bacillus Calmette-Guérin (BCG) | Janssen Research & Development, LLC | — | Phase 3 | — | — | — | — | — |
| A Study of CTX-009 in Combination With Paclitaxel in Adult Patients With Unresectable Advanced, Metastatic or Recurrent Biliary Tract Cancers (COMPANION-002) | Compass Therapeutics | — | PHASE2/PHASE3 | — | — | — | — | — |
| Efficacy of Gemcitabine Submucosal Injection for Preventing Recurrence in Intermediate- and High-Risk Non-Muscle-Invasive Bladder Cancer: A Randomized Trial | Shanghai University of Traditional Chinese Medicine | — | PHASE2/PHASE3 | — | — | — | — | — |
| Sapanisertib in Treating Patients With Locally Advanced or Metastatic Bladder Cancer With TSC1 and/or TSC2 Mutations | National Cancer Institute (NCI) | — | Phase 2 | — | — | — | — | — |
| Study of an Immunotherapeutic, DPX-Survivac, in Combination With Low Dose Cyclophosphamide & Pembrolizumab, in Subjects With Selected Advanced & Recurrent Solid Tumors | ImmunoVaccine Technologies, Inc. (IMV Inc.) | — | Phase 2 | — | — | — | — | — |
| Comparison of 18F-rhPSMA-7.3 PET/CT With and Without Furosemide in Biochemical Recurrence of Prostate Cancer | Emory University | — | Phase 2 | — | — | — | — | — |
| Fluorouracil, Leucovorin, Gemcitabine, and Cisplatin in Treating Patients With Metastatic or Unresectable Adenocarcinoma of the Urothelium or Urachal Remnant | M.D. Anderson Cancer Center | — | Phase 2 | — | — | — | — | — |
| 9MW2821 + Toripalimab vs 9MW2821 for 1st Line Locally Advanced or Metastatic Urothelial Carcinoma | Mabwell (Shanghai) Bioscience Co., Ltd. | — | Phase 2 | — | — | — | — | — |
| A Study of Oral Erdafitinib in People With Recurrent Non-Invasive Bladder Cancer | Memorial Sloan Kettering Cancer Center | — | Phase 2 | — | — | — | — | — |
| Adjuvant Sacituzumab Govitecan and Nivolumab in Muscle-Invasive Urothelial Carcinoma At High-Risk Recurrence | University of California, Irvine | — | Phase 2 | — | — | — | — | — |
| ARID1A and/or KDM6A Mutation and CXCL13 Expression | M.D. Anderson Cancer Center | — | Phase 2 | — | — | — | — | — |
| Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial) | National Cancer Institute (NCI) | — | Phase 2 | — | — | — | — | — |
| Clinical Trial of AM80 in Combination With Gemcitabine, Cisplatin, and Nivolumab in Patients With Urothelial Carcinoma | Nagoya University | — | Phase 2 | — | — | — | — | — |
| Atezolizumab With or Without Eribulin Mesylate in Treating Patients With Recurrent Locally Advanced or Metastatic Urothelial Cancer | National Cancer Institute (NCI) | — | Phase 2 | — | — | — | — | — |
| A Cruciferous Vegetable Eating Program for the Reduction of Cancer Recurrence and Progression in Patients With Non-muscle Invasive Bladder Cancer | Roswell Park Cancer Institute | — | Phase 2 | — | — | — | — | — |
| Dutasteride in Patients With Low Grade Non-muscle Invasive Bladder Cancer | Paul Toren | — | Phase 2 | — | — | — | — | — |
| Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to Radiation Therapy Compared to the Usual Chemotherapy Treatment During Radiation Therapy for Bladder Cancer, PARRC Trial | National Cancer Institute (NCI) | — | Phase 2 | — | — | — | — | — |
| Intravesical GEM/DOCE for HR BCG-Unresponsive NMIBC | Michael A. O'Donnell | — | Phase 2 | — | — | — | — | — |
| Eribulin Mesylate in Treating Patients With Locally Advanced or Metastatic Cancer of the Urothelium and Kidney Dysfunction | National Cancer Institute (NCI) | — | PHASE1/PHASE2 | — | — | — | — | — |
| Safety, Tolerability, and Preliminary Efficacy of BH011 in Subjects With Non-Muscle-Invasive Bladder Cancer | Zhuhai Beihai Biotech Co., Ltd | — | PHASE1/PHASE2 | — | — | — | — | — |
| Intravesical Cabazitaxel, Gemcitabine, and Cisplatin (CGC) in the Treatment Urothelial Carcinoma of the Bladder | Guarionex J. Decastro | — | PHASE1/PHASE2 | — | — | — | — | — |
| A Study of STM-416 Administered to Patients Undergoing TURBT for Recurrent Bladder Cancer | SURGE Therapeutics | — | PHASE1/PHASE2 | — | — | — | — | — |
| A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Patients With Bladder Cancer (MK-2870-027) | Merck Sharp & Dohme LLC | — | PHASE1/PHASE2 | — | — | — | — | — |